HK1214165A1 - 特定構象抗體生成和使用的方法和組合物 - Google Patents
特定構象抗體生成和使用的方法和組合物Info
- Publication number
- HK1214165A1 HK1214165A1 HK16102295.0A HK16102295A HK1214165A1 HK 1214165 A1 HK1214165 A1 HK 1214165A1 HK 16102295 A HK16102295 A HK 16102295A HK 1214165 A1 HK1214165 A1 HK 1214165A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- conformation
- bodies
- compositions
- generation
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792588P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/027017 WO2014152157A2 (en) | 2013-03-15 | 2014-03-14 | Methods and compositions for the generation and use of conformation-specific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1214165A1 true HK1214165A1 (zh) | 2016-07-22 |
Family
ID=51581680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16102295.0A HK1214165A1 (zh) | 2013-03-15 | 2016-02-26 | 特定構象抗體生成和使用的方法和組合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9688747B2 (zh) |
| EP (1) | EP2968548B1 (zh) |
| JP (1) | JP6448614B2 (zh) |
| CN (1) | CN105283196B (zh) |
| AU (1) | AU2014240063B2 (zh) |
| CA (1) | CA2903091C (zh) |
| ES (1) | ES2835716T3 (zh) |
| HK (1) | HK1214165A1 (zh) |
| WO (1) | WO2014152157A2 (zh) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8771693B2 (en) | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| US10485780B2 (en) | 2011-03-14 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of proliferative disorders |
| US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
| US9439884B2 (en) | 2011-05-26 | 2016-09-13 | Beth Israel Deaconess Medical Center, Inc. | Methods for the treatment of immune disorders |
| US9730941B2 (en) | 2012-06-07 | 2017-08-15 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of Pin1 |
| RU2018132044A (ru) | 2012-07-03 | 2018-10-19 | Вашингтон Юниверсити | Антитела против тау |
| PE20152004A1 (es) | 2013-03-13 | 2016-02-07 | Prothena Biosciences Ltd | Inmunoterapia tau |
| TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| WO2016011268A1 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Atra for modulating pin1 activity and stability |
| US10351914B2 (en) | 2014-07-17 | 2019-07-16 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for Pin1-associated disorders |
| TWI669314B (zh) * | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | 針對ｔａｕ之抗體及其用途 |
| US10548864B2 (en) | 2015-03-12 | 2020-02-04 | Beth Israel Deaconess Medical Center, Inc. | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
| WO2017011556A1 (en) * | 2015-07-13 | 2017-01-19 | The General Hospital Corporation | Rare phosphorylated high molecular weight (hmw) tau species that are involved in neuronal uptake and propagation and applications thereof |
| CN109071646A (zh) | 2016-03-11 | 2018-12-21 | 供石公司 | TGFβ1-结合免疫球蛋白及其用途 |
| KR102506091B1 (ko) | 2016-05-02 | 2023-03-07 | 프로테나 바이오사이언시즈 리미티드 | 타우 면역요법 |
| CU24537B1 (es) | 2016-05-02 | 2021-07-02 | Prothena Biosciences Ltd | Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6 |
| PE20190208A1 (es) | 2016-05-02 | 2019-02-07 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| IL268601B1 (en) | 2017-02-10 | 2024-03-01 | Univ Pennsylvania | Antibodies against factor D and their uses |
| CN110520440A (zh) | 2017-02-17 | 2019-11-29 | 戴纳立制药公司 | 抗τ抗体及其使用方法 |
| AU2018263935A1 (en) | 2017-05-02 | 2019-12-19 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CA3082365A1 (en) * | 2017-11-09 | 2019-05-16 | Pinteon Therapeutics Inc. | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies |
| WO2019175735A1 (en) * | 2018-03-11 | 2019-09-19 | Koorosh Shahpasand | Conformation-independent antibodies against neurotoxic tau proteins |
| JP2022524588A (ja) | 2019-03-03 | 2022-05-09 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| CN112979797B (zh) * | 2021-04-28 | 2022-04-01 | 中国检验检疫科学研究院 | 一种抗赤羽病病毒单克隆抗体及其制备方法与应用 |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
| CA2150803C (en) | 1992-12-02 | 2006-01-31 | Henry Auer | Controlled release growth hormone containing microspheres |
| US5861499A (en) | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
| US7473423B2 (en) | 1994-04-29 | 2009-01-06 | Mayo Foundation For Medical Education And Research | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| PT779806E (pt) | 1994-09-09 | 2001-02-28 | Takeda Chemical Industries Ltd | Preparacao de libertacao sustentada contendo um sal metalico de um peptido |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| PL184531B1 (pl) | 1995-06-07 | 2002-11-29 | Alkermes Inc | Kompozycja o opóźnionym uwalnianiu ludzkiego hormonu wzrostu do wytwarzania leku do terapii |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| US6706484B1 (en) | 1995-08-18 | 2004-03-16 | Morphosys Ag | Protein/(poly)peptide libraries |
| US6462173B1 (en) | 1997-09-08 | 2002-10-08 | Max-Planck-Gesellschaft Zur Forderung Der | Inhibitors of phosphoserine and phosphothreonine-proline-specific isomerases |
| US6441140B1 (en) | 1998-09-04 | 2002-08-27 | Cell Signaling Technology, Inc. | Production of motif-specific and context-independent antibodies using peptide libraries as antigens |
| EP1485130A4 (en) * | 2002-02-21 | 2006-11-22 | Univ Duke | REAGENTS AND TREATMENT PROCEDURES FOR AUTOIMMUNE DISEASES |
| US7161060B1 (en) * | 2002-07-16 | 2007-01-09 | Albert Einstein College Of Medicine Of Yeshiva University | Transgenic mice comprising a genomic human tau transgene |
| EP1484336A1 (en) | 2003-06-02 | 2004-12-08 | Pevion Biotech Ltd. | Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines |
| US20080058276A1 (en) | 2006-01-13 | 2008-03-06 | Cornell Research Foundation, Inc. | Alzheimer's disease therapeutics based on pin-1 catalyzed conformational changes in phosphorylated amyloid precursor protein |
| MX2008014710A (es) | 2006-05-19 | 2009-02-12 | Amgen Inc | Anticuerpos para coronavirus del sars. |
| US8529896B2 (en) * | 2007-10-16 | 2013-09-10 | Sbi Biotech Co., Ltd. | Anti-BST2 antibody |
| CN101965365A (zh) * | 2007-10-19 | 2011-02-02 | 伊缪纳斯制药株式会社 | 能够特异性结合Aβ寡聚体的抗体及其应用 |
| WO2011041518A1 (en) | 2009-10-02 | 2011-04-07 | The Regents Of The University Of California | Monoclonal antibodies |
| US8771693B2 (en) * | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
-
2014
- 2014-03-14 US US14/776,924 patent/US9688747B2/en active Active
- 2014-03-14 JP JP2016502309A patent/JP6448614B2/ja active Active
- 2014-03-14 WO PCT/US2014/027017 patent/WO2014152157A2/en active Application Filing
- 2014-03-14 EP EP14768309.8A patent/EP2968548B1/en active Active
- 2014-03-14 ES ES14768309T patent/ES2835716T3/es active Active
- 2014-03-14 CA CA2903091A patent/CA2903091C/en active Active
- 2014-03-14 CN CN201480015102.9A patent/CN105283196B/zh active Active
- 2014-03-14 AU AU2014240063A patent/AU2014240063B2/en active Active
-
2016
- 2016-02-26 HK HK16102295.0A patent/HK1214165A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2903091C (en) | 2022-09-06 |
| ES2835716T3 (es) | 2021-06-23 |
| EP2968548A2 (en) | 2016-01-20 |
| WO2014152157A3 (en) | 2014-12-24 |
| US9688747B2 (en) | 2017-06-27 |
| CN105283196A (zh) | 2016-01-27 |
| AU2014240063B2 (en) | 2019-04-11 |
| AU2014240063A1 (en) | 2015-09-17 |
| EP2968548B1 (en) | 2020-09-09 |
| WO2014152157A8 (en) | 2015-09-17 |
| US20160031977A1 (en) | 2016-02-04 |
| CA2903091A1 (en) | 2014-09-25 |
| EP2968548A4 (en) | 2016-11-30 |
| JP6448614B2 (ja) | 2019-01-09 |
| JP2016515129A (ja) | 2016-05-26 |
| WO2014152157A2 (en) | 2014-09-25 |
| CN105283196B (zh) | 2018-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1214165A1 (zh) | 特定構象抗體生成和使用的方法和組合物 | |
| IL289821A (en) | Preparations and methods for immunotherapy | |
| HK1220387A1 (zh) | 用於免疫療法的組合物和方法 | |
| EP3008170A4 (en) | SC-CELLS AND COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF | |
| HK1211866A1 (zh) | 抗氧化劑組合物及其使用方法 | |
| HK1214171A1 (zh) | 賽尼克韋羅組合物及其製備和使用方法 | |
| IL265876A (en) | Preparations that include 15-ohepa and methods of using them | |
| IL285527A (en) | Preparations and methods for immunotherapy | |
| PL2981303T3 (pl) | Kompozycja wypełniacza do leczenia lipoatrofii | |
| HK1220374A1 (zh) | 用於治療碳氧血紅蛋白血症的組合物和方法 | |
| GB201300628D0 (en) | Compositions comprising 15-OHEPA and methods of using the same |